Predictors of Success of a Single-Dose Methotrexate in the Treatment of Ectopic Pregnancy

被引：9

作者：

Alsammani M.A. ^{[1
,2
]}

Moona N.A. ^{[1
]}

机构：

[1] Department of Obstetrics & Gynecology, College of Medicine, Qassim University, P.O. Box 665, Buraidah

[2] Department of Obstetrics & Gynecology, College of Medicine, Bahri University, Khartoum

来源：

The Journal of Obstetrics and Gynecology of India | 2016年 / 66卷 / 4期

关键词：

Ectopic pregnancy; Methotrexate; Predictors of failure complications; Success rate;

D O I：

10.1007/s13224-014-0668-3

中图分类号：

学科分类号：

摘要：

Background: Ectopic pregnancy (EP) is the commonest cause of maternal mortality-related death in the first trimester. Methotrexate (MTX) remains the first-line treatment in optimally selected patients. Objective: To evaluate the success rate and predictors of success of a single-dose MTX treatment in EP. Subjects and Method: We studied retrospectively 109 patients with unruptured EP who were treated with Intramuscular MTX administered in a dose of 50 mg/m2 on days 0 and in additional doses on day 7 if β-hCG levels did not decrease by 15 % during the follow-up period. The study was conducted at the Maternity and Children Hospital Buraidah, Saudi Arabia from June 2013 to December 2013. Pretreatment β-β-hCG, EP mass diameter, peritoneal fluid, and fetal cardiac activity were evaluated. The main outcome measures were success rate, the predictors of success without surgical treatment. Result: Under this regime, the overall success rate was 60.6 % of patients. Of the failure group, only 4.7 % of patients experienced rupture of EP. No side effects were reported. The main predictors of failure were initial β-hCG value ≥ 3.500 mIU/mL OR 4.11 (1.646–12.248, 0.043) and EP diameter 3.73 (1.646–12.10, p = 0.003). Conclusion: The success rate of MTX in this study was 60.6 %, and the initial β-hCG concentration and EP diameter were the best predictors of successful treatment with MTX. Furthermore, MTX should be offered only to those patients with β-hCG <2,000 mIU/mL and EP mass size <3.5 cm. © 2015, Federation of Obstetric & Gynecological Societies of India.

引用

页码：233 / 238

页数：5

共 28 条

[1]

Barnhart K., Esposito M., Coutifaris C., An update on the medical treatment of ectopic pregnancy, Obstet Gynecol Clin, 27, pp. 653-657, (2000)

[2]

Shaw J.L., Diamandis E.P., Horne A.W., Et al., Ectopic pregnancy, Clin Chem., 58, pp. 1278-1285, (2012)

[3]

Pekhlivanov B., Milchev N., Conservative treatment of EP with MTX, Akush Ginekol (Sofiia)., 41, pp. 53-56, (2002)

[4]

Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists, Int J Gynecol Obstet, 1999, 65, pp. 97-103, (1998)

[5]

Barnhart K., Hummel A.C., Sammel M.D., Et al., Use of “2-dose” regimen of MTX to treat ectopic pregnancy, Fertil Steril, 87, pp. 250-256, (2007)

[6]

Menon S., Colins J., Barnhart K.T., Establishing a human chorionic gonadotropin cutoff to guide MTX treatment of ectopic pregnancy: a systematic review, Fertil Steril, 87, pp. 481-484, (2007)

[7]

Barnhart K.T., Gosman G., Ashby R., Et al., The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens, Obstet Gynecol, 101, (2003)

[8]

Farquhar C.M., Ectopic pregnancy, Lancet, 366, pp. 583-591, (2005)

[9]

Morlock R.J., Lafata J.E., Eisenstein D., Cost-effectiveness of single-dose MTX compared with laparoscopic treatment of ectopic pregnancy, Obstet Gynecol, 95, (2000)

[10]

Gnisci A., Stefani L., Bottin P., Et al., Predictive value of hemoperitoneum for outcome of MTX treatment in ectopic pregnancy: an observational comparative study, Ultrasound Obstet Gynecol, 43, pp. 698-701, (2014)

← 1 2 3 →